• Vaccine Ontology ID: VO_0011510
• Type: Subunit vaccine
• Status: Research
• CEACAM5 (CEA) gene engineering:
  • Type: Recombinant protein preparation
  • Detailed Gene Information: Click Here.
• Vector: Dendritic Cells (Bae et al., 2009).
• Immunization Route: Intramuscular injection (i.m.)

Mouse Response

• Host Strain: B6
• Vaccination Protocol: To establish a CEA-positive tumour-bearing mouse model, 6-week-old B6 mice were injected in the right flank with MC38-CEA2 cells (1 × 106) each. At 7 days after tumour cell injection, mice were immunized at the tail base with DCs pulsed with CEA or Tat-CEA proteins (1 × 106 cells/mouse in 100 µl PBS) at weekly intervals for 4 weeks. Control mice were injected with PBS only (Bae et al., 2009).
• Challenge Protocol: To establish a CEA-positive tumour-bearing mouse model, 6-week-old B6 mice were injected in the right flank with MC38-CEA2 cells (1 × 106) each (Bae et al., 2009).
• Efficacy: In vivo, the DC (Tat-CEA) vaccine delayed tumour growth significantly and prolonged survival of tumour-bearing mice (Bae et al., 2009).